Integrative Oncology & Cancer Immunotherapy Services

We offer RGCC Tests for Detection, Analysis and Monitoring. The aim of RGCC and our cancer blood tests is to detect, analyze and examine cancer cells early at every stage of the disease.

As medical research and technology continues to advance, the cancer blood test and other RGCC tests offer promising opportunities for early cancer detection and treatment. In this process, the focus is always on providing doctors and patients with a clinical basis on which they can make well-founded and personalized decisions for individual cancer treatment and therapy.

Q-REstrain consists of microRNA molecules with the ability to regulate the gene expression of a specific target. The short dsRNAs (double-stranded RNAs) are derived by cleavage of long dsRNA from Dicer and can be microRNAs (miRNAs). miRNAs then assemble with RNA-induced silencing complex (RISC) and cause gene silencing. RNAi has been used in the therapy of different diseases including cancer, viral infections, respiratory diseases, etc. Targeting of specific proteins, through degradation of their mRNA, is very common in cancer treatment of different types of cancer or other infections.
Q-REstrain contains microRNAs isolated by the patient’s sample, leading to the degradation of specific mRNA molecules, which are overexpressed in this specific sample, thus regulating the expression. Q-REstrain is for autologous use only and is provided through the RGCC network.

Clavic-Q-RE is an adoptive cell therapy aiming to generate a robust anti-tumor immune response. Clavi-Q-RE contains different cell populations, isolated by the patient’s sample. They include monocytes, natural killer cells, as well as dendritic cells that are already activated in vivo against tumor antigens, which are expressed on cancer samples, cytotoxic T lymphocytes, and plasma cells that have been already differentiated in vivo against tumor antigens. Clavic-Q-RE is for autologous use only and is provided through the RGCC network.

Vaccine Prep (ATA) is a new type of immunotherapy that activates or strengthens specific immune cells. The body's own cells are specifically designed to recognize and destroy cancer cells. We use the cellular fragments of dying tumor cells (CTCs). These include organelles, mitochondria, cell membranes and cellular RNA and DNA. In our laboratory, we stimulate the development of dendritic cells and thus promote tumor antigen therapy.

The aim of dendritic cell therapy is to activate or strengthen the immune system. In immunotherapy, specific immune cells are used to target cancer cells. The therapy method uses so-called dendritic cells, which can recognize specific antigens on the surface of cancer cells. Thanks to improved tumor defense and a reduction in systemic side effects, the therapy is considered a promising treatment approach.

Learn More